Efruxifermin (EFX) placebo
Sponsors
Akero Therapeutics Inc.
Conditions
FibrosisMetabolic Dysfunction-Associated Steatohepatitis (MASH)Non Alcoholic Steatohepatitis (NASH)
Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Safety And Efficacy Of Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic
Dysfunction-Associated Steatohepatitis (MASH) And Fibrosis
RecruitingCTIS2023-505141-48-00
Start: 2024-03-07Target: 244Updated: 2026-01-22
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
RecruitingCTIS2024-512895-36-00
Start: 2024-11-25Target: 170Updated: 2025-12-04